Your browser doesn't support javascript.
loading
Low Eosinophil Percentages as a New Predictive Marker for Infusion Reactions Due to Trastuzumab.
Takahashi, Masaya; Takahashi, Katsuyuki; Matsumoto, Saya; Takashima, Tsutomu; Asano, Yuka; Morisaki, Tamami; Kashiwagi, Shinichiro; Noda, Satoru; Onoda, Naoyoshi; Ohira, Masaichi; Nagayama, Katsuya.
Afiliación
  • Takahashi M; Department of Pharmacy, Osaka City University Hospital, Osaka, Japan.
  • Takahashi K; Department of Pharmacy, Osaka City University Hospital, Osaka, Japan k.taka@med.osaka-cu.ac.jp.
  • Matsumoto S; Department of Pharmacy, Osaka City University Hospital, Osaka, Japan.
  • Takashima T; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
  • Asano Y; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
  • Morisaki T; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
  • Kashiwagi S; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
  • Noda S; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
  • Onoda N; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
  • Ohira M; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
  • Nagayama K; Department of Pharmacy, Osaka City University Hospital, Osaka, Japan.
Anticancer Res ; 40(7): 4047-4051, 2020 Jul.
Article en En | MEDLINE | ID: mdl-32620651
ABSTRACT
BACKGROUND/

AIM:

Infusion reactions (IRs) often occur with trastuzumab. Although premedication by non-steroidal anti-inflammatory drugs can be effective to a certain extent, IRs are still common and infrequently severe. Therefore, a predictive marker that can select patients requiring further prophylaxis is useful for appropriate prevention, but remains unclear. PATIENTS AND

METHODS:

We conducted a retrospective analysis for 136 consecutive female inpatients aged 18 years and older who received 8 mg/kg of the initial trastuzumab administration for breast cancer with a 25-mg dose of rectal diclofenac before trastuzumab infusion between May 2007 and April 2019, in order to assess IRs.

RESULTS:

Overall, 57 patients were eligible for inclusion in the study. IRs were observed in 17.5% (10/57) of the patients. Univariate analysis showed that patients with a low eosinophil percentage (≤2%) were associated with IRs (p=0.016).

CONCLUSION:

A low eosinophil percentage can be a useful new predictive marker for trastuzumab-induced IRs in patients with breast cancer.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Eosinófilos / Trastuzumab / Reacción en el Punto de Inyección / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Middle aged Idioma: En Revista: Anticancer Res Año: 2020 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Eosinófilos / Trastuzumab / Reacción en el Punto de Inyección / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Middle aged Idioma: En Revista: Anticancer Res Año: 2020 Tipo del documento: Article País de afiliación: Japón